Skip to content

IMMUCELL CORPORATION

NASDAQ: ICCC

Company: ImmuCell Corporation
Ticker: Nasdaq: ICCC
Sector: Healthcare
Investor Contact: Joe Diaz

ImmuCell Corporation Financials

Financials – Current & Historical

BALANCE SHEETS
v3.25.1
Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:    
Cash and cash equivalents $ 3,758,232 $ 978,741
Trade accounts receivable 3,771,133 2,185,383
Inventory 7,112,623 7,811,841
Prepaid expenses and other current assets 400,762 493,885
Total current assets 15,042,750 11,469,850
Property, plant and equipment, net 25,349,019 27,575,683
Operating lease right-of-use asset 4,560,679 4,571,149
Goodwill 95,557 95,557
Intangible assets, net 19,104 38,208
Other assets 33,368 57,655
TOTAL ASSETS 45,100,477 43,808,102
CURRENT LIABILITIES:    
Current portion of debt obligations 1,497,619 1,428,807
Current portion of operating lease liability 432,072 644,276
Accounts payable and accrued expenses 2,482,522 2,124,337
Total current liabilities 4,412,213 4,197,420
LONG-TERM LIABILITIES:    
Debt obligations, net of current portion 9,040,975 10,540,496
Operating lease liability, net of current portion 4,129,102 4,077,109
Total long-term liabilities 13,170,077 14,617,605
TOTAL LIABILITIES 17,582,290 18,815,025
CONTINGENT LIABILITIES AND COMMITMENTS
STOCKHOLDERS’ EQUITY:    
Common stock, $0.10 par value per share, with 15,000,000 shares authorized and 9,042,392 and 7,814,165 shares issued and 8,979,091 and 7,750,864 shares outstanding as of December 31, 2024 and 2023, respectively 904,240 781,417
Additional paid-in capital 40,916,155 36,357,239
Accumulated deficit (14,163,726) (12,007,097)
Treasury stock, at cost, 63,301 shares as of both December 31, 2024 and 2023 (138,482) (138,482)
Total stockholders’ equity 27,518,187 24,993,077
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 45,100,477 $ 43,808,102
STATEMENTS OF INCOME
v3.25.1
Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Product sales $ 26,493,169 $ 17,471,669
Costs of goods sold 18,552,125 13,602,385
Gross margin 7,941,044 3,869,284
Product development expenses 3,898,582 4,394,852
Sales and marketing expenses 3,466,072 3,088,215
Administrative expenses 2,216,549 2,134,295
Operating expenses 9,581,203 9,617,362
NET OPERATING LOSS (1,640,159) (5,748,078)
Other expenses, net 506,414 21,893
LOSS BEFORE INCOME TAXES (2,146,573) (5,769,971)
Income tax expense 10,056 4,627
NET LOSS $ (2,156,629) $ (5,774,598)
Basic weighted average common shares outstanding (in Shares) 8,167,244 7,747,686
Basic net loss per share (in Dollars per share) $ (0.26) $ (0.75)
Diluted weighted average common shares outstanding (in Shares) 8,167,244 7,747,686
Diluted net loss per share (in Dollars per share) $ (0.26) $ (0.75)
STATEMENTS OF CASH FLOWS
v3.25.1
Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (2,156,629) $ (5,774,598)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:    
Depreciation 2,668,077 2,697,897
Amortization of intangible assets 19,104 19,104
Amortization of debt issuance costs and debt discounts 42,666 22,619
Stock-based compensation 325,551 368,866
Loss on disposal of property, plant and equipment 15,391 8,099
Non-cash rent (benefit) expense (149,741) 95,724
Changes in:    
Trade accounts receivable (1,585,750) (426,783)
Inventory 699,218 (1,773,302)
Prepaid expenses and other current assets 93,123 (87,830)
Other assets 24,287 18,973
Accounts payable and accrued expenses 362,606 156,995
Net cash provided by (used for) operating activities 357,903 (4,674,236)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property, plant and equipment (465,725) (1,892,513)
Proceeds from sale of property, plant and equipment 4,500 2,474
Net cash used for investing activities (461,225) (1,890,039)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from debt issuance 3,000,000
Proceeds from line of credit 2,000,000
Proceeds from At-The-Market Offering 4,648,022
Debt principal repayments (1,468,338) (1,185,774)
Line of credit repayments (2,000,000)
Payments of debt issuance costs (5,037) (35,425)
Payments of debt discounts (46,107)
Payments of equity issuance fees (291,834)
Proceeds from exercise of stock options 18,760
Net cash provided by financing activities 2,882,813 1,751,454
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 2,779,491 (4,812,821)
BEGINNING CASH AND CASH EQUIVALENTS 978,741 5,791,562
ENDING CASH AND CASH EQUIVALENTS 3,758,232 978,741
CASH PAID FOR:    
Income taxes 7,293 6,466
Interest 528,907 444,954
NON-CASH ACTIVITIES:    
Change in capital expenditures included in accounts payable and accrued expenses 4,421 50,086
Change in payments of debt discounts included in accounts payable and accrued expenses 16,566
Operating lease right-of-use asset and operating lease liability $ 103,115 $ 2,472,203

Arrow